Transgene receives $15.3 Million from the Sale of Securities Held for Sale

information fournie par Boursorama CP •17/07/2023 à 17:45

Transgene receives $15.3 Million from the Sale of Securities Held for Sale

Strasbourg, France, July 17, 2023, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3 million (€ 14.0 million) as a result of the full disposal of its minority stake in a Chinese biopharmaceutical company.

Following this transaction, which completion was expected for mid-2023, Transgene reaffirms its financial visibility until early 2024.

Contacts
Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04

Media: MEDiSTRAVA Consulting
David Dible/Sylvie Berrebi
+44 (0)203 928 6900
transgene@medistrava.com